8-K 1 v03208e8vk.htm FORM 8-K e8vk
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 8, 2004

NASTECH PHARMACEUTICAL COMPANY INC.

(Exact name of registrant as specified in charter)
                 
DELAWARE   0-13789   11-2658569  
(State or other jurisdiction
of incorporation		   (Commission
File Number)		   (IRS Employer
Identification No.)		    
                 
                 
3450 Monte Villa Parkway
Bothell, Washington		             98021  
(Address of principal executive offices)             (Zip Code)  

425-908-3600
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

Item 8.01 Other Events.
Item 9.01 Financial Statements and Exhibits
SIGNATURES
Exhibit Index
EXHIBIT 99.1

Table of Contents

Item 8.01 Other Events.

On November 8, 2004, Nastech Pharmaceutical Company Inc. (the “Registrant”) issued a press release in which it announced that the Company has entered into separate agreements with two undisclosed research partners to evaluate the development of proprietary formulations for the nasal delivery of compounds useful for the treatment of type 2 diabetes and Alzheimer’s disease. Financial terms were not disclosed.

In connection with the foregoing, the Registrant hereby furnishes the following exhibit:

Item 9.01 Financial Statements and Exhibits

(c)   Exhibits.

         
Exhibit Number
   Description
99.1
   Press Release of Nastech Pharmaceutical Company Inc. dated November 8, 2004.

Table of Contents

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

           
  Nastech Pharmaceutical Company Inc.
  (Registrant)
       
       
       
 
By:
   /s/ Gregory L. Weaver  
 
 
  
 		    
 
Name:
   Gregory L. Weaver
 
Title:
   Chief Financial Officer

Dated:
November 12, 2004

Table of Contents

Exhibit Index

         
Exhibit Number
   Description
  
99.1
   Press Release of Nastech Pharmaceutical Company Inc. dated November 8, 2004.